# TICKET-021 Verification Specification
## Test Protocol Context Enhancement

**Ticket ID:** TICKET-021
**Feature:** Add Test Protocol Context to Standards Output
**Created:** 2026-02-15
**Status:** Verification Specification - Ready for Implementation
**Expert Requirement:** Standards Testing Engineer (15+ years experience)

---

## Executive Summary

This verification specification defines how to validate that TICKET-021 successfully addresses the expert panel's critical finding: **"Tool provides standard numbers without actionable information"** (Expert Panel Review, lines 154-182).

**Current Gap:**
```
Tool Output: "ISO 10993-1:2018 - Biological Evaluation"
```

**Required Enhancement:**
```
Tool Output:
  Standard: ISO 10993-1:2018 - Biological Evaluation
  Required Sections: 5 (cytotoxicity), 10 (irritation), 11 (sensitization)
  Sample Sizes: N=5 (cyto), N=3 (irritation), N=20 (sensitization)
  Estimated Cost: $12,000 - $18,000
  Lead Time: 6-8 weeks
  Accredited Labs: [Nelson Labs, WuXi AppTec, NAMSA] (3 labs)
  Protocol Template: Available
```

**Success Criteria:** Testing engineers can use tool output to **directly plan test programs** without manual research.

---

## 1. Test Protocol Mapping Verification

### 1.1 Standard Section Extraction Verification

**Requirement:** Each standard must include specific test sections (not just overall standard number).

**Verification Method:**

```json
{
  "standard": "ISO 10993-1:2018",
  "required_sections": [
    {
      "section": "5.1",
      "title": "Cytotoxicity testing",
      "mandatory": true,
      "applies_to": "ALL devices with patient contact"
    },
    {
      "section": "5.2",
      "title": "Sensitization testing",
      "mandatory": true,
      "applies_to": "Devices with skin contact >24 hours OR repeated contact"
    },
    {
      "section": "5.3",
      "title": "Irritation testing",
      "mandatory": true,
      "applies_to": "Devices with mucosal membrane or compromised skin contact"
    },
    {
      "section": "5.4",
      "title": "Systemic toxicity (acute)",
      "mandatory": false,
      "applies_to": "Blood-contacting devices OR long-term implants (>30 days)"
    },
    {
      "section": "5.5",
      "title": "Subchronic toxicity",
      "mandatory": false,
      "applies_to": "Permanent implants (>30 days contact)"
    },
    {
      "section": "5.6",
      "title": "Genotoxicity",
      "mandatory": true,
      "applies_to": "ALL devices with patient contact"
    },
    {
      "section": "5.7",
      "title": "Implantation",
      "mandatory": false,
      "applies_to": "Surgically invasive devices contacting bone or tissue"
    },
    {
      "section": "5.8",
      "title": "Hemocompatibility",
      "mandatory": false,
      "applies_to": "Blood-contacting devices (circulating or external)"
    }
  ]
}
```

**Test Cases:**

| Device Type | Expected Sections | Verification Source |
|-------------|------------------|-------------------|
| **Cardiovascular catheter (DQY)** | 5.1, 5.2, 5.3, 5.4, 5.6, 5.8 | ISO 10993-1 Table A.1, Contact: Blood (circulating) |
| **Spinal implant (OVE)** | 5.1, 5.2, 5.4, 5.5, 5.6, 5.7 | ISO 10993-1 Table A.1, Contact: Tissue/bone (permanent) |
| **Wound dressing (FRO)** | 5.1, 5.2, 5.3, 5.6 | ISO 10993-1 Table A.1, Contact: Skin/wound (limited <24h) |
| **Electrosurgical unit (GEI)** | NONE (no patient-contacting parts) | Exclusion: External non-contact device |

**Acceptance Criteria:**
- ‚úÖ **100%** of biocompatibility standards include section-level breakdown
- ‚úÖ **Mandatory vs. optional** sections clearly identified
- ‚úÖ **Device-specific applicability** rules based on contact type/duration
- ‚úÖ **Exclusion logic** documented for non-applicable devices

**Verification Data Source:**
- ISO 10993-1:2018 Table A.1 (Categorization by Body Contact)
- FDA Guidance: "Use of ISO 10993-1, Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process" (June 2016, updated 2020)

---

### 1.2 Cross-Reference to FDA Guidance

**Requirement:** Section mapping must align with FDA-specific expectations (not just standard text).

**Verification Method:**

| Standard | FDA Guidance Reference | FDA-Specific Expectations |
|----------|----------------------|--------------------------|
| **ISO 10993-1** | FDA Guidance "Use of ISO 10993-1" (June 2016) | ‚Ä¢ Chemical characterization REQUIRED before testing<br>‚Ä¢ Pyrogenicity testing if blood contact<br>‚Ä¢ Carcinogenicity for permanent implants |
| **IEC 60601-1** | FDA Guidance "Recognition of IEC 60601-1" (2020) | ‚Ä¢ ANSI/AAMI ES60601-1:2005/(R)2012 + A1:2012 + AMD 1:2020 required<br>‚Ä¢ Particular standards (e.g., -2-27 for anesthesia) may be mandated |
| **ISO 11135** | FDA Guidance "Sterilization Process Validation" (1993) | ‚Ä¢ EO residuals testing per ISO 10993-7<br>‚Ä¢ Validation protocol pre-approval for Class III |
| **IEC 62304** | FDA Guidance "Content of Premarket Submissions for Software" (2005) | ‚Ä¢ Class C software requires ALL lifecycle phases documented<br>‚Ä¢ SOUP analysis mandatory |

**Test Case Example (Cardiovascular Catheter):**

```json
{
  "standard": "ISO 10993-1:2018",
  "fda_guidance_overlay": {
    "guidance_document": "Use of ISO 10993-1 (2016)",
    "fda_additions": [
      "Chemical characterization per ISO 10993-18 BEFORE biological testing",
      "Pyrogenicity testing per USP <151> for blood-contacting devices",
      "Thrombogenicity evaluation per ISO 10993-4 (blood-contacting devices)"
    ],
    "fda_modifications": [
      "ISO 10993-1 Table A.1 is GUIDANCE, not prescriptive - FDA may require additional endpoints"
    ]
  }
}
```

**Acceptance Criteria:**
- ‚úÖ **100%** of FDA-recognized standards include guidance document citation
- ‚úÖ **FDA-specific additions** highlighted (e.g., chemical characterization first)
- ‚úÖ **Division-specific expectations** noted (e.g., CDRH/Radiological Health for IEC 60601-1)

---

## 2. Sample Size Calculation Verification

### 2.1 Statistical Basis for Sample Sizes

**Requirement:** Sample sizes must cite specific standard section AND statistical rationale.

**Verification Method:**

```json
{
  "standard": "ISO 10993-5:2009",
  "test": "In vitro cytotoxicity",
  "sample_size": {
    "n": 5,
    "replicates": 3,
    "total_samples": 15,
    "citation": "ISO 10993-5:2009, Section 8.3.2",
    "statistical_basis": "N=5 devices √ó 3 replicates provides 95% confidence for qualitative pass/fail",
    "acceptance_criteria": "‚â§10% cell lysis vs. negative control"
  }
}
```

**Standard-Specific Sample Size Database:**

| Standard | Test | Section | N (devices) | Replicates | Total | Citation |
|----------|------|---------|-------------|-----------|-------|----------|
| **ISO 10993-5** | Cytotoxicity | 8.3.2 | 5 | 3 | 15 | "Representative samples from production" |
| **ISO 10993-10** | Skin sensitization | 7.3 | 20 | 1 (animals) | 20 | "Guinea pig maximization test: 10 test + 10 control" |
| **ISO 10993-10** | Skin irritation | 6.3 | 3 | 1 (animals) | 3 | "Rabbit primary irritation: 3 animals minimum" |
| **ISO 10993-11** | Systemic toxicity (acute) | 6.3 | 10 | 1 (animals) | 10 | "Mice or rats: 5 test + 5 control" |
| **ASTM F1717** | Spinal construct strength | 7.2 | 6 | 1 | 6 | "Minimum 6 constructs for statistical validity" |
| **IEC 60601-1** | Electrical safety | Various | 3 | 1 | 3 | "Type test: 3 production units minimum (Clause 5.4.2)" |

**FDA Guidance Overlay (When FDA Requires MORE):**

| Standard | Test | Standard N | FDA Expectation | FDA Source |
|----------|------|-----------|----------------|------------|
| **ISO 11135** | EO sterilization validation | 10 per load config | 30 (3 runs √ó 10 units) | FDA Sterilization Guidance 1993 |
| **ISO 10993-11** | Chronic toxicity (implants) | 20 animals | 40 animals (2 species) | FDA Blue Book Memo G95-1 |
| **ASTM F2181** | Transcatheter heart valve fatigue | 1 valve √ó 400M cycles | 3 valves √ó 400M cycles | FDA Guidance "Heart Valves" 2010 |

**Test Case (Spinal Fusion Device, OVE):**

```json
{
  "device": "Cervical spinal fusion cage with PEEK+titanium",
  "product_code": "OVE",
  "biocompatibility_samples": {
    "iso_10993_5_cytotoxicity": {
      "n_devices": 5,
      "replicates": 3,
      "total": 15,
      "cost_per_sample": "$150",
      "total_cost": "$2,250",
      "lead_time": "2 weeks"
    },
    "iso_10993_10_sensitization": {
      "n_animals": 20,
      "test_method": "Guinea pig maximization test (GPMT)",
      "total": 20,
      "cost_per_animal": "$800",
      "total_cost": "$16,000",
      "lead_time": "6 weeks"
    },
    "iso_10993_11_systemic_toxicity": {
      "n_animals": 10,
      "species": "Mice (5 test + 5 control)",
      "total": 10,
      "cost_per_animal": "$600",
      "total_cost": "$6,000",
      "lead_time": "4 weeks"
    }
  },
  "mechanical_samples": {
    "astm_f1717_compression": {
      "n_constructs": 6,
      "test_config": "Compression to failure",
      "total": 6,
      "cost_per_construct": "$2,500",
      "total_cost": "$15,000",
      "lead_time": "3 weeks"
    }
  },
  "total_testing_cost": "$39,250",
  "critical_path_lead_time": "6 weeks (sensitization)"
}
```

**Acceptance Criteria:**
- ‚úÖ **‚â•90%** of sample sizes match published standard requirements
- ‚úÖ **100%** of sample sizes include specific section citation (e.g., "ISO 10993-5, Section 8.3.2")
- ‚úÖ **FDA overlay** documented when FDA expects larger samples than standard
- ‚úÖ **Statistical basis** explained (not just "N=5" without rationale)

---

### 2.2 Device Type Considerations

**Requirement:** Sample sizes must adjust based on device complexity and risk.

**Verification Method:**

| Device Category | Standard Sample Size | Device-Specific Adjustments |
|-----------------|---------------------|---------------------------|
| **Implants (permanent)** | ISO 10993-5: N=5 | +ISO 10993-11 (chronic): N=40 animals (2 species)<br>+ISO 10993-6 (degradation): N=10 √ó 5 time points |
| **Combination devices** | Standard testing | +Drug interaction studies<br>+Separate device and drug biocompatibility |
| **Sterile reusable devices** | ISO 17664: 3 cycles | +AAMI ST79: 10 reprocessing cycles<br>+Worst-case soiling validation |
| **Software (SaMD)** | IEC 62304: N/A (code testing) | +Clinical validation: 150-300 cases (per FDA AI/ML Guidance)<br>+Subgroup analysis: ‚â•30 cases per demographic |

**Test Case (AI Diabetic Retinopathy Screening, QKQ):**

```json
{
  "device": "AI-powered diabetic retinopathy screening software",
  "product_code": "QKQ",
  "software_testing": {
    "iec_62304_unit_tests": {
      "sample_size": "N/A (code coverage metric: ‚â•80%)",
      "cost": "$15,000 - $25,000",
      "lead_time": "4 weeks"
    }
  },
  "clinical_validation": {
    "fda_expectation": "Per 2022 Clinical Decision Support Guidance",
    "primary_cohort": {
      "total_images": 300,
      "sensitivity_target": "‚â•85% (vs. ophthalmologist ground truth)",
      "specificity_target": "‚â•90%",
      "cost": "$50,000 - $80,000",
      "lead_time": "12 weeks"
    },
    "subgroup_analysis": {
      "ethnicity_subgroups": 5,
      "min_per_subgroup": 30,
      "total": 150,
      "purpose": "Bias detection per FDA AI/ML Action Plan",
      "cost": "$25,000 - $40,000",
      "lead_time": "8 weeks (concurrent with primary)"
    }
  },
  "total_validation_cost": "$90,000 - $145,000",
  "critical_path_lead_time": "12 weeks"
}
```

**Acceptance Criteria:**
- ‚úÖ **Device-specific adjustments** documented for implants, combination products, SaMD
- ‚úÖ **FDA guidance overlay** included for novel device types (e.g., AI/ML)
- ‚úÖ **Worst-case scenarios** identified (e.g., reprocessing validation)

---

## 3. Cost Estimation Accuracy

### 3.1 Laboratory Quote Verification

**Requirement:** Cost ranges must reflect ACTUAL laboratory quotes (dated within 12 months).

**Verification Method:**

**Spot-Check Protocol (20% of standards):**

1. Select 20% of standards randomly from each category:
   - Biocompatibility: 2 standards (e.g., ISO 10993-5, ISO 10993-10)
   - Electrical Safety: 1 standard (e.g., IEC 60601-1)
   - Sterilization: 1 standard (e.g., ISO 11135)
   - Mechanical: 1 standard (e.g., ASTM F1717)

2. Obtain quotes from ‚â•3 ISO/IEC 17025 accredited labs:
   - Lab A: High-volume commercial lab (e.g., Nelson Labs, NAMSA)
   - Lab B: Mid-tier specialized lab (e.g., WuXi AppTec)
   - Lab C: Academic or low-cost lab (if available)

3. Compare tool estimates vs. actual quotes:

| Standard | Test | Tool Estimate | Lab A Quote | Lab B Quote | Lab C Quote | Within ¬±30%? |
|----------|------|--------------|-------------|-------------|-------------|--------------|
| **ISO 10993-5** | Cytotoxicity (N=15) | $2,000 - $3,500 | $2,800 | $2,200 | $1,900 | ‚úÖ YES |
| **ISO 10993-10** | GPMT Sensitization | $14,000 - $18,000 | $16,500 | $17,200 | N/A (not offered) | ‚úÖ YES |
| **IEC 60601-1** | Full electrical safety | $15,000 - $25,000 | $22,000 | $19,500 | $28,000 | ‚úÖ YES |
| **ISO 11135** | EO validation (3 runs) | $35,000 - $50,000 | $42,000 | $38,000 | N/A | ‚úÖ YES |
| **ASTM F1717** | Spinal construct (N=6) | $12,000 - $18,000 | $14,500 | $16,800 | $11,000 | ‚úÖ YES |

**Acceptance Criteria:**
- ‚úÖ **‚â•80%** of spot-checked costs within ¬±30% of actual lab quotes
- ‚úÖ **100%** of cost ranges updated within 12 months
- ‚úÖ **‚â•3 lab quotes** used to establish range (not single source)

**Data Source Documentation:**

```json
{
  "standard": "ISO 10993-5:2009",
  "test": "In vitro cytotoxicity (N=15 samples)",
  "cost_range": {
    "low": 2000,
    "high": 3500,
    "currency": "USD",
    "last_updated": "2026-01-15",
    "sources": [
      {
        "lab": "Nelson Labs (Salt Lake City, UT)",
        "quote_date": "2026-01-10",
        "amount": 2800,
        "scope": "Extract method, MEM elution, L929 mouse fibroblasts"
      },
      {
        "lab": "NAMSA (Northwood, OH)",
        "quote_date": "2026-01-08",
        "amount": 2200,
        "scope": "Extract method, direct contact, L929 cells"
      },
      {
        "lab": "WuXi AppTec (St. Paul, MN)",
        "quote_date": "2025-12-20",
        "amount": 1900,
        "scope": "Extract method, MEM elution, CHO cells"
      }
    ],
    "notes": "Costs assume client provides 5 devices. Add $500-$1000 for protocol development if not provided."
  }
}
```

---

### 3.2 Cost Range Width and Clarity

**Requirement:** Costs must be ranges (not point estimates) that account for protocol variability.

**Verification Method:**

**Acceptable Cost Ranges:**

| Test Complexity | Range Width | Example |
|----------------|-------------|---------|
| **Simple in vitro** | ¬±25% | ISO 10993-5 cytotoxicity: $2,000 - $3,500 (75% spread) |
| **Complex in vivo** | ¬±30% | ISO 10993-10 sensitization: $14,000 - $20,000 (43% spread) |
| **Full system test** | ¬±40% | IEC 60601-1 electrical safety: $15,000 - $25,000 (67% spread) |
| **Novel/custom** | ¬±50% | Bioeffects validation (no consensus standard): $50,000 - $100,000 (100% spread) |

**UNACCEPTABLE (Too Narrow):**
- ‚ùå "ISO 10993-5: $2,500" (no range = user doesn't know variability)
- ‚ùå "IEC 60601-1: $20,000 ¬± $1,000" (¬±5% is unrealistic for complex test)

**ACCEPTABLE:**
- ‚úÖ "ISO 10993-5: $2,000 - $3,500" (clear range)
- ‚úÖ "IEC 60601-1: $15,000 - $25,000 (varies by device class, collateral standards)" (range + context)

**Acceptance Criteria:**
- ‚úÖ **100%** of costs are ranges (not single values)
- ‚úÖ **Range width** appropriate to test complexity (see table above)
- ‚úÖ **Contextual notes** explain variability (e.g., "Add $5K if wireless testing needed")

---

### 3.3 Total Project Cost Rollup

**Requirement:** Tool must calculate total testing cost for device (sum all applicable standards).

**Verification Method:**

**Test Case (Cardiovascular Catheter, DQY):**

```json
{
  "device": "Intravascular catheter for diagnostic use",
  "product_code": "DQY",
  "testing_cost_breakdown": {
    "biocompatibility": {
      "iso_10993_5": { "cost_range": [2000, 3500], "description": "Cytotoxicity" },
      "iso_10993_10": { "cost_range": [14000, 20000], "description": "Sensitization + Irritation" },
      "iso_10993_11": { "cost_range": [8000, 12000], "description": "Systemic toxicity (acute)" },
      "iso_10993_4": { "cost_range": [25000, 35000], "description": "Thrombogenicity (blood contact)" },
      "subtotal_range": [49000, 70500]
    },
    "performance_testing": {
      "iso_11070": { "cost_range": [8000, 12000], "description": "Dimensional verification" },
      "tensile_strength": { "cost_range": [5000, 8000], "description": "ASTM F2394 kink resistance" },
      "subtotal_range": [13000, 20000]
    },
    "sterilization": {
      "iso_11135": { "cost_range": [35000, 50000], "description": "EO validation (3 runs)" },
      "iso_10993_7": { "cost_range": [5000, 8000], "description": "EO residuals" },
      "subtotal_range": [40000, 58000]
    },
    "TOTAL_COST_RANGE": {
      "minimum": 102000,
      "maximum": 148500,
      "average": 125250,
      "confidence": "¬±20% (protocol-dependent)"
    }
  }
}
```

**Acceptance Criteria:**
- ‚úÖ **Total cost rollup** calculated for all applicable standards
- ‚úÖ **Min/Max/Average** clearly presented
- ‚úÖ **Confidence interval** explained (e.g., "¬±20% based on protocol variability")
- ‚úÖ **Cost verified reasonable** (e.g., $100K-$150K for Class II catheter is realistic)

**Reasonableness Check:**

| Device Class | Typical Total Testing Cost | Example |
|--------------|---------------------------|---------|
| **Class I (exempt)** | $5,000 - $15,000 | Basic biocompatibility only |
| **Class II (moderate risk)** | $50,000 - $150,000 | Biocompat + performance + sterilization |
| **Class II (high complexity)** | $150,000 - $400,000 | Implants, powered devices, combination products |
| **Class III (PMA)** | $500,000 - $2,000,000 | Full preclinical + clinical + GLP toxicology |

---

## 4. Lead Time Validation

### 4.1 Laboratory Capacity Verification

**Requirement:** Lead times must reflect typical laboratory turnaround times (not theoretical minimums).

**Verification Method:**

**Lead Time Components:**

```
Total Lead Time = Sample Prep + Lab Queue + Testing + Report
```

| Standard | Test | Sample Prep | Lab Queue | Testing Duration | Report Writing | Total Lead Time |
|----------|------|-------------|-----------|------------------|----------------|----------------|
| **ISO 10993-5** | Cytotoxicity | 1 week | 1 week | 3 days | 3 days | **2-3 weeks** |
| **ISO 10993-10** | GPMT Sensitization | 1 week | 2 weeks | 3 weeks | 1 week | **6-8 weeks** |
| **ISO 10993-11** | Systemic toxicity | 1 week | 2 weeks | 2 weeks | 1 week | **5-7 weeks** |
| **IEC 60601-1** | Electrical safety | 2 weeks | 1 week | 2 weeks | 1 week | **5-7 weeks** |
| **ISO 11135** | EO validation | 4 weeks | 2 weeks | 3 weeks | 2 weeks | **10-12 weeks** |
| **ASTM F1717** | Spinal construct | 2 weeks | 1 week | 1 week | 1 week | **4-6 weeks** |

**Peak Season Adjustments (Q4 rush for January submissions):**

| Season | Lab Queue Multiplier | Example Impact |
|--------|---------------------|----------------|
| **Q1-Q2** (low season) | 1.0x | ISO 10993-10: 6 weeks (baseline) |
| **Q3** (moderate) | 1.2x | ISO 10993-10: 7 weeks (+1 week queue) |
| **Q4** (high season) | 1.5x | ISO 10993-10: 9 weeks (+3 weeks queue) |

**Acceptance Criteria:**
- ‚úÖ **‚â•80%** of lead times within ¬±2 weeks of actual lab turnaround
- ‚úÖ **Lab queue time** explicitly included (not just testing duration)
- ‚úÖ **Sample prep time** included (client often underestimates this)
- ‚úÖ **Seasonal variability** noted (Q4 rush warning)

**Data Source:**

```json
{
  "standard": "ISO 10993-10:2010",
  "test": "Guinea pig maximization test (GPMT)",
  "lead_time": {
    "total_weeks": "6-8",
    "breakdown": {
      "sample_prep": "1 week (client provides extracts)",
      "lab_queue": "1-2 weeks (depends on season)",
      "testing": "3 weeks (GPMT protocol duration)",
      "report": "1 week (draft report delivery)"
    },
    "sources": [
      {
        "lab": "Nelson Labs",
        "typical_turnaround": "7 weeks",
        "quote_date": "2026-01-10"
      },
      {
        "lab": "NAMSA",
        "typical_turnaround": "6 weeks",
        "quote_date": "2026-01-08"
      }
    ],
    "rush_available": {
      "available": true,
      "reduction": "2 weeks",
      "cost_premium": "+30% ($5,000)",
      "conditions": "Subject to lab capacity"
    }
  }
}
```

---

### 4.2 Sequential vs. Parallel Testing

**Requirement:** Lead time must account for dependencies between tests.

**Verification Method:**

**Sequential Dependencies (CRITICAL PATH):**

| Dependency | Reason | Impact |
|------------|--------|--------|
| **Chemical characterization ‚Üí Biocompatibility** | ISO 10993-18 required BEFORE ISO 10993-5 | +4 weeks |
| **Material qualification ‚Üí Mechanical testing** | Must verify material composition before ASTM tests | +2 weeks |
| **Sterilization validation ‚Üí Biocompatibility** | Must test sterile device (not raw material) | +10 weeks |
| **Software V&V ‚Üí Clinical validation** | IEC 62304 complete before clinical study | +12 weeks |

**Test Case (Implant with CRITICAL PATH):**

```json
{
  "device": "PEEK spinal fusion cage with titanium coating",
  "product_code": "OVE",
  "testing_sequence": {
    "phase_1_material_characterization": {
      "tests": ["ISO 10993-18 chemical characterization"],
      "duration": "4 weeks",
      "parallel": false,
      "blocks": ["All biocompatibility testing"]
    },
    "phase_2_biocompatibility": {
      "tests": [
        "ISO 10993-5 (cytotoxicity)",
        "ISO 10993-10 (sensitization/irritation)",
        "ISO 10993-11 (systemic toxicity)"
      ],
      "duration": "8 weeks (parallel execution)",
      "parallel": true,
      "critical_path": "ISO 10993-10 (8 weeks)",
      "depends_on": ["Phase 1"]
    },
    "phase_3_mechanical_testing": {
      "tests": [
        "ASTM F1717 (compression)",
        "ASTM F2077 (subsidence)"
      ],
      "duration": "6 weeks (parallel execution)",
      "parallel": true,
      "depends_on": ["Phase 1 (material verification)"]
    },
    "phase_4_sterilization_validation": {
      "tests": ["ISO 11135 (EO validation)"],
      "duration": "12 weeks",
      "parallel": false,
      "blocks": ["Final biocompatibility on sterile device"]
    },
    "CRITICAL_PATH_ANALYSIS": {
      "path": "Phase 1 ‚Üí Phase 2 ‚Üí Phase 4",
      "total_duration": "24 weeks (6 months)",
      "parallel_savings": "6 weeks (Phase 3 runs during Phase 2+4)",
      "actual_calendar_time": "24 weeks"
    }
  }
}
```

**Acceptance Criteria:**
- ‚úÖ **Sequential dependencies** explicitly documented
- ‚úÖ **Parallel testing opportunities** identified
- ‚úÖ **Critical path** calculated (longest chain of dependencies)
- ‚úÖ **Calendar time** vs. **testing duration** distinguished (e.g., 30 weeks testing ‚Üí 24 weeks calendar if parallelized)

---

### 4.3 Rush Service Availability

**Requirement:** Tool must indicate when expedited testing is available (and cost premium).

**Verification Method:**

| Standard | Test | Standard Lead Time | Rush Available? | Rush Lead Time | Cost Premium |
|----------|------|-------------------|----------------|----------------|--------------|
| **ISO 10993-5** | Cytotoxicity | 2-3 weeks | ‚úÖ YES | 1 week | +20% ($400) |
| **ISO 10993-10** | GPMT Sensitization | 6-8 weeks | ‚ùå NO | N/A | N/A (animal protocol cannot be shortened) |
| **IEC 60601-1** | Electrical safety | 5-7 weeks | ‚úÖ YES | 3 weeks | +30% ($6,000) |
| **ISO 11135** | EO validation | 10-12 weeks | ‚ö†Ô∏è LIMITED | 8 weeks | +50% ($20,000) (if lab has capacity) |

**Acceptance Criteria:**
- ‚úÖ **Rush options** documented for ‚â•50% of standards
- ‚úÖ **Cost premium** specified (e.g., "+30%")
- ‚úÖ **Limitations** noted (e.g., "Animal studies cannot be rushed")
- ‚úÖ **Conditions** specified (e.g., "Subject to lab availability")

---

## 5. Accredited Lab Directory Verification

### 5.1 ISO/IEC 17025 Accreditation Verification

**Requirement:** 100% of listed labs must have valid ISO/IEC 17025 accreditation for specific test method.

**Verification Protocol:**

**For Each Listed Lab:**

1. **Verify Accreditation Existence:**
   - Check ANAB (ANSI National Accreditation Board): https://anab.ansi.org/accreditation/accredited-organizations
   - Check A2LA (American Association for Laboratory Accreditation): https://www.a2la.org/directory
   - Check International (ILAC): https://ilac.org/

2. **Verify Scope:**
   - Download lab's Scope of Accreditation certificate
   - Confirm specific standard/method is listed (e.g., "ISO 10993-5:2009 In vitro cytotoxicity")
   - Verify accreditation is CURRENT (not expired)

3. **Verify FDA Recognition (for foreign labs):**
   - Check FDA's list of foreign testing labs: https://www.fda.gov/medical-devices/cdrh-international-program/accreditation-scheme-conformity-assessment-asca

**Example Verification Record:**

```json
{
  "lab_name": "Nelson Laboratories",
  "location": "6280 S. Redwood Rd, Salt Lake City, UT 84123",
  "accreditation": {
    "body": "A2LA",
    "certificate_number": "2382.01",
    "issue_date": "2025-06-15",
    "expiry_date": "2027-06-14",
    "status": "VALID",
    "verification_date": "2026-02-15",
    "verification_url": "https://www.a2la.org/scopepdf/2382-01.pdf"
  },
  "scope_includes": [
    "ISO 10993-5:2009 - Cytotoxicity (extract and direct contact methods)",
    "ISO 10993-10:2010 - Sensitization (GPMT, LLNA)",
    "ISO 10993-11:2017 - Systemic toxicity",
    "ISO 11135:2014 - EO sterilization validation"
  ],
  "fda_recognition": {
    "recognized": true,
    "program": "ASCA (Accreditation Scheme for Conformity Assessment)",
    "recognition_date": "2024-01-10"
  },
  "contact": {
    "phone": "+1-801-290-7500",
    "email": "info@nelsonlabs.com",
    "website": "https://www.nelsonlabs.com",
    "last_verified": "2026-02-15"
  }
}
```

**Acceptance Criteria:**
- ‚úÖ **100%** of listed labs have valid ISO/IEC 17025 accreditation
- ‚úÖ **100%** of labs are accredited for SPECIFIC standard/method (not generic accreditation)
- ‚úÖ **Accreditation expiry dates** verified current (within last 12 months)
- ‚úÖ **FDA recognition** verified for foreign labs

---

### 5.2 Geographic Coverage

**Requirement:** Lab directory must include ‚â•3 labs per standard, covering US/EU/Asia.

**Verification Method:**

| Standard | Test | US Labs | EU Labs | Asia Labs | Total |
|----------|------|---------|---------|-----------|-------|
| **ISO 10993-5** | Cytotoxicity | Nelson (UT)<br>NAMSA (OH)<br>Charles River (MA) | BSI (UK)<br>T√úV S√úD (DE) | WuXi (CN)<br>Intertek (JP) | **7 labs** ‚úÖ |
| **IEC 60601-1** | Electrical safety | Intertek (OR)<br>T√úV Rheinland (CA) | T√úV S√úD (DE)<br>BSI (UK) | CQC (CN)<br>T√úV Rheinland (HK) | **6 labs** ‚úÖ |
| **ISO 11135** | EO validation | Nelson (UT)<br>Steris (OH) | Synergy (UK) | N/A (limited) | **3 labs** ‚úÖ |
| **ASTM F1717** | Spinal construct | Exponent (CA)<br>Smithers (OH) | Underwriters Labs (DE) | Intertek (CN) | **4 labs** ‚úÖ |

**Acceptance Criteria:**
- ‚úÖ **‚â•3 labs** per standard (minimum diversity)
- ‚úÖ **Geographic coverage:** US + (EU OR Asia) minimum
- ‚úÖ **Lab specialties** noted (e.g., "Steris specializes in sterilization validation")

---

### 5.3 Contact Information Accuracy

**Requirement:** Lab contact info (phone, email, website) must be current and verified.

**Verification Method:**

**Quarterly Verification Process:**

1. **Automated Website Check:**
   - Verify lab website URL returns HTTP 200 (not 404)
   - Check for redirect (if URL changed, update record)

2. **Email Verification:**
   - Send test email to lab's general inquiry address
   - Verify delivery (no bounce)

3. **Phone Verification (Spot Check 20%):**
   - Call lab's main number
   - Confirm lab still operates at listed address
   - Verify they still offer listed test services

**Acceptance Criteria:**
- ‚úÖ **100%** of lab websites accessible (HTTP 200)
- ‚úÖ **100%** of lab emails valid (no bounce)
- ‚úÖ **‚â•95%** of phone numbers functional (spot-check 20%)
- ‚úÖ **Contact info updated** within 12 months

**Maintenance Trigger:**
- If ‚â•2 labs have stale contact info ‚Üí CRITICAL (update all labs in database)
- If ‚â•5 labs have accreditation expiring within 60 days ‚Üí WARNING (verify renewals)

---

## 6. Test Protocol Template Verification

### 6.1 Template Completeness

**Requirement:** Templates must cover ALL required sections per standard (not partial/generic).

**Verification Method:**

**ISO 10993-5 Cytotoxicity Template Checklist:**

| Required Section | Standard Reference | Included in Template? | Device-Specific Placeholders? |
|-----------------|-------------------|---------------------|------------------------------|
| **1. Test Article Description** | ISO 10993-5, Clause 7 | ‚úÖ YES | ‚úÖ [DEVICE NAME], [MATERIALS], [CONTACT TYPE] |
| **2. Test Method Selection** | ISO 10993-5, Clause 8 | ‚úÖ YES | ‚úÖ [EXTRACT/DIRECT CONTACT] based on device |
| **3. Extract Preparation** | ISO 10993-5, Clause 8.2 | ‚úÖ YES | ‚úÖ [EXTRACTION VEHICLE], [TEMPERATURE], [DURATION] |
| **4. Cell Line Selection** | ISO 10993-5, Clause 8.3 | ‚úÖ YES | ‚úÖ L929 mouse fibroblasts (default) OR [CELL LINE] |
| **5. Test Procedure** | ISO 10993-5, Clause 8.4 | ‚úÖ YES | ‚úÖ 3 replicates √ó 5 devices (N=15 samples) |
| **6. Positive/Negative Controls** | ISO 10993-5, Clause 8.5 | ‚úÖ YES | ‚úÖ DMSO (positive), HDPE (negative) |
| **7. Acceptance Criteria** | ISO 10993-5, Clause 9 | ‚úÖ YES | ‚úÖ ‚â§10% cell lysis vs. negative control = PASS |
| **8. Statistical Analysis** | ISO 10993-5, Clause 10 | ‚úÖ YES | ‚úÖ One-way ANOVA, p<0.05 |
| **9. Report Format** | ISO 10993-5, Clause 11 | ‚úÖ YES | ‚úÖ ISO 17025 report template |

**Acceptance Criteria:**
- ‚úÖ **100%** of templates cover all required standard sections
- ‚úÖ **Device-specific placeholders** included (not generic one-size-fits-all)
- ‚úÖ **Acceptance criteria** unambiguous (pass/fail clearly defined)

---

### 6.2 Device-Specific Customization

**Requirement:** Templates must include conditional logic based on device type.

**Verification Method:**

**Example: ISO 10993-1 Biological Evaluation Plan Template**

```markdown
# Biological Evaluation Plan (BEP)
## Device: [DEVICE NAME]
## Product Code: [XXX]

### Contact Categorization (per ISO 10993-1 Table A.1)

**Contact Type:**
- [ ] Surface device (skin only)
- [ ] External communicating (mucosal membrane)
- [ ] Implant device (tissue/bone contact)

**Contact Duration:**
- [ ] Limited (<24 hours)
- [ ] Prolonged (24 hours to 30 days)
- [ ] Permanent (>30 days)

### Required Endpoints (Auto-Generated Based on Above)

**IF Contact = Surface + Limited:**
- ‚úÖ Cytotoxicity (ISO 10993-5)
- ‚úÖ Sensitization (ISO 10993-10)
- ‚úÖ Irritation (ISO 10993-10)
- ‚ùå Systemic toxicity (NOT required)
- ‚ùå Hemocompatibility (NOT required)

**IF Contact = Implant + Permanent:**
- ‚úÖ Cytotoxicity (ISO 10993-5)
- ‚úÖ Sensitization (ISO 10993-10)
- ‚úÖ Systemic toxicity - Subchronic (ISO 10993-11)
- ‚úÖ Genotoxicity (ISO 10993-3)
- ‚úÖ Implantation (ISO 10993-6)
- ‚ö†Ô∏è Carcinogenicity (ISO 10993-3) - if metallic implant
- ‚ùå Hemocompatibility (NOT required unless blood contact)

**IF Contact = Blood-contacting + ANY duration:**
- ‚úÖ Hemocompatibility (ISO 10993-4) - **MANDATORY**
- ‚úÖ Thrombogenicity (ISO 10993-4, Annex E)
- ‚úÖ Complement activation (ISO 10993-4, Annex C)
```

**Acceptance Criteria:**
- ‚úÖ **Conditional logic** implemented (e.g., IF/THEN rules)
- ‚úÖ **Device type selection** triggers appropriate sections
- ‚úÖ **Exclusions documented** (e.g., "NOT required because...")

---

### 6.3 FDA Alignment

**Requirement:** Templates must align with FDA expectations (not just international standards).

**Verification Method:**

**FDA-Specific Template Additions:**

| Standard | International Version | FDA Modifications | Template Includes? |
|----------|---------------------|------------------|-------------------|
| **ISO 10993-1** | Table A.1 endpoints | FDA expects chemical characterization (ISO 10993-18) FIRST | ‚úÖ Step 0: Chemical characterization |
| **IEC 60601-1** | Edition 3.1 (2012) | FDA recognizes ANSI/AAMI ES60601-1:2005/(R)2012 + AMD 1:2020 | ‚úÖ Correct edition cited |
| **ISO 14971** | ISO 14971:2019 | FDA also expects EN ISO 14971:2019/A11:2021 (EU amendment) | ‚ö†Ô∏è Both versions noted |
| **IEC 62304** | Software lifecycle | FDA expects SOUP analysis per 2005 Guidance | ‚úÖ SOUP section included |

**Test Case (Cardiovascular Catheter Template):**

```markdown
## ISO 10993-4 Hemocompatibility Testing

### FDA-Specific Requirements (per FDA Guidance "Use of ISO 10993-4")

‚ö†Ô∏è **CRITICAL:** FDA expects the following tests for blood-contacting devices:

1. **Thrombosis Testing** (ISO 10993-4, Annex E)
   - Method: Ex vivo arteriovenous shunt (rabbit or primate)
   - Duration: ‚â•1 hour continuous blood contact
   - Acceptance: Thrombus weight ‚â§ predicate device

2. **Complement Activation** (ISO 10993-4, Annex C)
   - Method: C3a and SC5b-9 ELISA
   - Acceptance: <150% baseline (FDA expectation, not in standard)

3. **Platelet Activation** (ISO 10993-4, Annex D)
   - Method: Œ≤-thromboglobulin release
   - Acceptance: <120% baseline

4. **Coagulation Cascade** (ISO 10993-4, Annex B)
   - Tests: aPTT, PT, fibrinogen
   - Acceptance: Within normal physiological range

### Device-Specific Considerations

**IF [DEVICE] contacts blood for <1 hour (diagnostic catheter):**
- Simplified panel: Thrombosis + Platelet activation (minimum)

**IF [DEVICE] contacts blood >24 hours (indwelling catheter):**
- Full panel: All 4 tests REQUIRED
```

**Acceptance Criteria:**
- ‚úÖ **FDA guidance** cited where applicable
- ‚úÖ **FDA-specific expectations** highlighted (e.g., acceptance criteria stricter than standard)
- ‚úÖ **Division preferences** noted (e.g., CDRH/Radiological Health for IEC 60601-1)

---

## 7. Acceptance Criteria for Context Data

### 7.1 Quantitative Metrics

**CRITICAL:** The following metrics define "PASS" for TICKET-021 implementation.

| Data Category | Metric | Target | Verification Method |
|--------------|--------|--------|---------------------|
| **Sample Size Accuracy** | Match published standard requirements | ‚â•90% | Spot-check 20 standards vs. standard text |
| **Cost Accuracy** | Within ¬±30% of actual lab quotes | ‚â•80% | Obtain quotes for 10 standards (2 per category) |
| **Lead Time Accuracy** | Within ¬±2 weeks of actual lab turnaround | ‚â•80% | Obtain lead times for 10 standards |
| **Lab Accreditation** | Valid ISO/IEC 17025 accreditation | 100% | Verify accreditation for ALL listed labs |
| **Template Completeness** | Covers all required standard sections | 100% | Checklist verification (see 6.1) |
| **Contact Information** | Current within 12 months | 100% | Quarterly verification (website/email/phone) |

**Overall Acceptance Criteria:**

```
PASS: ALL 6 metrics meet targets
CONDITIONAL PASS: 5/6 metrics meet targets (1 deficiency documented, fix within 30 days)
FAIL: ‚â§4 metrics meet targets (requires rework before release)
```

---

### 7.2 Qualitative Metrics (Expert Evaluation)

**Requirement:** Standards Testing Engineer with 12+ years experience must evaluate tool output.

**Evaluation Criteria:**

| Question | Acceptable Answer |
|----------|------------------|
| **1. Can you use this output to plan a test program WITHOUT additional research?** | YES (for ‚â•80% of devices) |
| **2. Are sample sizes realistic and defensible to FDA?** | YES (all sample sizes cite standard section) |
| **3. Are cost estimates useful for budgeting?** | YES (ranges are realistic, not misleading) |
| **4. Are lead times actionable for project planning?** | YES (account for dependencies and lab queues) |
| **5. Are lab recommendations trustworthy?** | YES (100% accredited, contact info current) |
| **6. Are templates usable without modification?** | MOSTLY (80% usable, 20% need minor device-specific tweaks) |

**Acceptance Criteria:**
- ‚úÖ **‚â•5/6 questions** answered YES
- ‚úÖ **Expert provides written sign-off** (see Section 10)

---

## 8. Test Cases by Standard Category

### 8.1 Biocompatibility (ISO 10993-1)

**Test Case: Verify Sample Sizes for Cytotoxicity**

**Input:**
- Device: Silicone wound dressing
- Contact: Skin (limited <24 hours)

**Expected Output:**

```json
{
  "standard": "ISO 10993-5:2009",
  "test": "In vitro cytotoxicity",
  "sample_size": {
    "n_devices": 5,
    "replicates": 3,
    "total_samples": 15,
    "citation": "ISO 10993-5:2009, Section 8.3.2",
    "rationale": "Representative samples from production lots"
  },
  "cost": {
    "range": [2000, 3500],
    "currency": "USD",
    "includes": "Extract preparation, MEM elution, L929 cell culture, report"
  },
  "lead_time": "2-3 weeks",
  "labs": [
    {
      "name": "Nelson Labs",
      "location": "Salt Lake City, UT",
      "accreditation": "A2LA #2382.01 (expires 2027-06-14)",
      "contact": "info@nelsonlabs.com"
    }
  ],
  "protocol_template": "Available"
}
```

**Verification:**
- ‚úÖ N=5 matches ISO 10993-5, Section 8.3.2
- ‚úÖ Cost $2,000-$3,500 matches Nelson Labs quote ($2,800)
- ‚úÖ Lead time 2-3 weeks matches lab turnaround
- ‚úÖ Lab accreditation verified current

---

### 8.2 Electrical Safety (IEC 60601-1)

**Test Case: Verify Cost for Full Compliance Test**

**Input:**
- Device: Electrosurgical unit (line-powered, 400W)
- Class: II (moderate risk)

**Expected Output:**

```json
{
  "standard": "IEC 60601-1:2005+A1:2012+A2:2020",
  "test": "Full electrical safety compliance",
  "test_sections": [
    "Clause 8 - Electrical hazards (leakage current, dielectric strength)",
    "Clause 9 - Mechanical hazards",
    "Clause 11 - Temperature limits",
    "Clause 13 - Hazardous outputs (high voltage, energy)",
    "Clause 15 - Programmable electrical medical systems (if applicable)"
  ],
  "sample_size": {
    "n_devices": 3,
    "citation": "IEC 60601-1, Clause 5.4.2 (Type test)",
    "rationale": "3 production units minimum for statistical validity"
  },
  "cost": {
    "range": [15000, 25000],
    "currency": "USD",
    "notes": "Add $5K if wireless communication (IEC 60601-1-2 radiated emissions)",
    "includes": "Type test (3 units), test report, certificate of compliance"
  },
  "lead_time": "5-7 weeks",
  "labs": [
    {
      "name": "Intertek",
      "location": "Boxborough, MA",
      "accreditation": "ANAB (NRTL, ISO 17025)",
      "contact": "medical@intertek.com"
    },
    {
      "name": "T√úV Rheinland",
      "location": "Fremont, CA",
      "accreditation": "ANAB (NRTL, ISO 17025)",
      "contact": "medical@tuv.com"
    }
  ],
  "protocol_template": "Available"
}
```

**Verification:**
- ‚úÖ Cost $15K-$25K matches Intertek quote ($22K)
- ‚úÖ N=3 matches IEC 60601-1, Clause 5.4.2
- ‚úÖ Wireless note included (critical for cost estimation)

---

### 8.3 Sterilization (ISO 11135)

**Test Case: Verify Lead Time for EO Validation**

**Input:**
- Device: Catheter (labeled sterile, EO sterilization)
- Configuration: Single load config

**Expected Output:**

```json
{
  "standard": "ISO 11135:2014",
  "test": "Ethylene oxide sterilization validation",
  "phases": [
    {
      "phase": "Installation Qualification (IQ)",
      "duration": "1 week",
      "description": "Verify sterilizer equipment meets specs"
    },
    {
      "phase": "Operational Qualification (OQ)",
      "duration": "2 weeks",
      "description": "Verify sterilizer operates within parameters"
    },
    {
      "phase": "Performance Qualification (PQ)",
      "duration": "3 weeks",
      "description": "3 consecutive validation runs with biological indicators"
    },
    {
      "phase": "Report generation",
      "duration": "2 weeks",
      "description": "Validation report and certificate"
    }
  ],
  "sample_size": {
    "n_devices": 30,
    "breakdown": "3 runs √ó 10 devices per run (worst-case loading)",
    "citation": "ISO 11135:2014, Clause 10.3",
    "fda_expectation": "FDA expects ‚â•3 runs (per 1993 Sterilization Guidance)"
  },
  "cost": {
    "range": [35000, 50000],
    "currency": "USD",
    "notes": "Assumes client provides sterilizer. Add $50K if lab sterilizer used."
  },
  "lead_time": {
    "total": "10-12 weeks",
    "critical_path": "Sequential phases (IQ ‚Üí OQ ‚Üí PQ ‚Üí Report)"
  },
  "labs": [
    {
      "name": "Nelson Labs",
      "location": "Salt Lake City, UT",
      "specialization": "EO sterilization validation (Class I-III devices)"
    },
    {
      "name": "Steris Labs",
      "location": "Columbus, OH",
      "specialization": "Contract sterilization + validation services"
    }
  ]
}
```

**Verification:**
- ‚úÖ Lead time 10-12 weeks matches Nelson Labs quote (11 weeks)
- ‚úÖ Sequential phases documented (cannot parallelize)
- ‚úÖ FDA expectation (3 runs) highlighted

---

### 8.4 Software (IEC 62304)

**Test Case: Verify Template Includes All Lifecycle Phases**

**Input:**
- Device: AI-powered diabetic retinopathy screening software
- Software Class: C (high risk - impacts patient treatment)

**Expected Output:**

```json
{
  "standard": "IEC 62304:2006+A1:2015",
  "lifecycle_phases": [
    {
      "phase": "5.1 - Software Development Planning",
      "mandatory": true,
      "deliverables": ["Software Development Plan", "Risk Management Plan"]
    },
    {
      "phase": "5.2 - Software Requirements Analysis",
      "mandatory": true,
      "deliverables": ["Software Requirements Specification (SRS)", "Traceability matrix"]
    },
    {
      "phase": "5.3 - Software Architectural Design",
      "mandatory": true,
      "deliverables": ["Software Design Specification (SDS)", "SOUP analysis"]
    },
    {
      "phase": "5.4 - Software Detailed Design",
      "mandatory": true,
      "deliverables": ["Detailed design documents", "Unit test plan"]
    },
    {
      "phase": "5.5 - Software Unit Implementation and Verification",
      "mandatory": true,
      "deliverables": ["Source code", "Unit test results (‚â•80% code coverage for Class C)"]
    },
    {
      "phase": "5.6 - Software Integration and Integration Testing",
      "mandatory": true,
      "deliverables": ["Integration test plan", "Integration test results"]
    },
    {
      "phase": "5.7 - Software System Testing",
      "mandatory": true,
      "deliverables": ["System test plan", "System test results", "Traceability to SRS"]
    },
    {
      "phase": "5.8 - Software Release",
      "mandatory": true,
      "deliverables": ["Release notes", "Known anomalies list"]
    }
  ],
  "fda_specific": {
    "guidance": "Content of Premarket Submissions for Software (2005)",
    "additional_requirements": [
      "Software Bill of Materials (SBOM) - per 2023 Cybersecurity Guidance",
      "SOUP (Software of Unknown Provenance) analysis - libraries, frameworks",
      "Cybersecurity design documentation - threat modeling, vulnerability management"
    ]
  },
  "sample_size": "N/A (documentation-based, not testing)",
  "cost": {
    "range": [50000, 150000],
    "currency": "USD",
    "notes": "Highly variable - depends on code complexity, SOUP count, security requirements",
    "breakdown": {
      "documentation": [15000, 40000],
      "code_review": [10000, 30000],
      "testing": [25000, 80000]
    }
  },
  "lead_time": "12-20 weeks (depends on software maturity)"
}
```

**Verification:**
- ‚úÖ All 8 lifecycle phases (5.1-5.8) included
- ‚úÖ Class C requirements specified (unit test coverage ‚â•80%)
- ‚úÖ FDA SOUP analysis noted (critical for FDA review)

---

## 9. Integration Testing

### 9.1 Tool Output + Context Integration

**Requirement:** Context data must integrate seamlessly with existing tool output (not separate file).

**Verification Method:**

**BEFORE (Current Tool Output):**

```
Standards for Device: Intravascular Catheter (DQY)

1. ISO 10993-1:2018 - Biological Evaluation of Medical Devices - Part 1
   Confidence: HIGH
   Applicability: ALL devices with patient contact

2. ISO 11070:2015 - Sterile Intravascular Catheters
   Confidence: HIGH
   Applicability: Intravascular catheters (product code DQY)

3. IEC 60601-1:2005+A1:2012 - Medical Electrical Equipment
   Confidence: MEDIUM
   Applicability: Electrically powered devices

Total: 3 standards
```

**AFTER (With TICKET-021 Context):**

```
Standards for Device: Intravascular Catheter (DQY)

‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ

1. ISO 10993-1:2018 - Biological Evaluation of Medical Devices - Part 1
   Confidence: HIGH
   Applicability: ALL devices with patient contact (blood, circulating)

   üìã Required Test Sections:
   ‚Ä¢ 5.1 - Cytotoxicity (ISO 10993-5)
   ‚Ä¢ 5.2 - Sensitization (ISO 10993-10)
   ‚Ä¢ 5.3 - Irritation (ISO 10993-10)
   ‚Ä¢ 5.4 - Systemic toxicity, acute (ISO 10993-11)
   ‚Ä¢ 5.6 - Genotoxicity (ISO 10993-3)
   ‚Ä¢ 5.8 - Hemocompatibility (ISO 10993-4) ‚ö†Ô∏è CRITICAL for blood contact

   üìä Sample Sizes:
   ‚Ä¢ Cytotoxicity: N=5 devices √ó 3 replicates = 15 samples
   ‚Ä¢ Sensitization: N=20 animals (guinea pig maximization test)
   ‚Ä¢ Hemocompatibility: N=6 devices (thrombosis, complement, platelet tests)

   üí∞ Estimated Cost: $49,000 - $70,500
   ‚Ä¢ Cytotoxicity: $2,000 - $3,500
   ‚Ä¢ Sensitization: $14,000 - $20,000
   ‚Ä¢ Systemic toxicity: $8,000 - $12,000
   ‚Ä¢ Hemocompatibility: $25,000 - $35,000

   ‚è±Ô∏è  Lead Time: 8-10 weeks (critical path: sensitization 6-8 weeks)

   üè≠ Accredited Labs (3):
   ‚Ä¢ Nelson Labs (Salt Lake City, UT) - A2LA #2382.01
     Contact: info@nelsonlabs.com | +1-801-290-7500
   ‚Ä¢ NAMSA (Northwood, OH) - A2LA #2382.02
     Contact: info@namsa.com | +1-419-666-9455
   ‚Ä¢ WuXi AppTec (St. Paul, MN) - A2LA #5378.01
     Contact: info@wuxiapptec.com | +1-651-603-7800

   üìù Protocol Template: Available (ISO 10993-1 Biological Evaluation Plan)

‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ

2. ISO 11070:2015 - Sterile Intravascular Catheters
   Confidence: HIGH
   Applicability: Intravascular catheters (product code DQY)

   üìã Required Test Sections:
   ‚Ä¢ Clause 5.2 - Dimensional verification (length, diameter, wall thickness)
   ‚Ä¢ Clause 5.3 - Tensile strength (catheter shaft)
   ‚Ä¢ Clause 5.4 - Kink resistance
   ‚Ä¢ Clause 5.5 - Flow rate (if applicable)

   üìä Sample Sizes:
   ‚Ä¢ Dimensional: N=10 catheters (per size)
   ‚Ä¢ Tensile strength: N=10 catheters
   ‚Ä¢ Kink resistance: N=10 catheters

   üí∞ Estimated Cost: $8,000 - $12,000

   ‚è±Ô∏è  Lead Time: 3-4 weeks

   üè≠ Accredited Labs (2):
   ‚Ä¢ Smithers (Akron, OH) - A2LA certified
   ‚Ä¢ Exponent (Menlo Park, CA) - A2LA certified

   üìù Protocol Template: Available

‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ

3. IEC 60601-1:2005+A1:2012 - Medical Electrical Equipment
   Confidence: MEDIUM
   Applicability: Electrically powered devices (if catheter has sensors/electronics)

   ‚ö†Ô∏è  CONDITIONAL: Only applies if catheter has electrical components (e.g., pressure sensor)

   üìã Required Test Sections:
   ‚Ä¢ Clause 8 - Electrical hazards (leakage current)
   ‚Ä¢ Clause 11 - Temperature limits
   ‚Ä¢ IEC 60601-1-2 - EMC (electromagnetic compatibility)

   üìä Sample Sizes:
   ‚Ä¢ Type test: N=3 devices

   üí∞ Estimated Cost: $15,000 - $25,000

   ‚è±Ô∏è  Lead Time: 5-7 weeks

   üè≠ Accredited Labs (3):
   ‚Ä¢ Intertek (Boxborough, MA) - NRTL + ISO 17025
   ‚Ä¢ T√úV Rheinland (Fremont, CA) - NRTL + ISO 17025
   ‚Ä¢ UL (Northbrook, IL) - NRTL + ISO 17025

   üìù Protocol Template: Available

‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ‚îÅ

TOTAL ESTIMATED TESTING COST: $72,000 - $107,500
CRITICAL PATH LEAD TIME: 10 weeks (biocompatibility sensitization)

‚ö†Ô∏è  NOTES:
‚Ä¢ Costs assume client provides devices/samples
‚Ä¢ Lead times assume standard lab queue (not rush service)
‚Ä¢ Sequential dependencies: Chemical characterization (ISO 10993-18) BEFORE biocompatibility testing
‚Ä¢ FDA Pre-Submission recommended for novel device features

üìß Export options: [CSV] [PDF] [JSON]
```

**Acceptance Criteria:**
- ‚úÖ **Context integrated** into existing output format (not separate file)
- ‚úÖ **Visual hierarchy** clear (emoji icons, separators)
- ‚úÖ **Total cost rollup** prominently displayed
- ‚úÖ **Critical path** identified (longest lead time)
- ‚úÖ **Warnings/notes** highlighted (e.g., conditional standards, FDA Pre-Sub)

---

### 9.2 Conditional Context Based on Device Type

**Requirement:** Context must adapt based on device characteristics (not static).

**Verification Method:**

**Test Case 1: Non-Sterile Device**

```
Device: Diagnostic stethoscope (non-sterile, non-powered)
ISO 10993-1: Biocompatibility testing ONLY (no sterilization)
ISO 11135: NOT APPLICABLE ‚úÖ (device not labeled sterile)
```

**Test Case 2: Sterile Device**

```
Device: Sterile surgical scalpel
ISO 10993-1: Biocompatibility testing
ISO 11135: ‚úÖ REQUIRED (device labeled sterile)
  Additional context: Sterilization validation ($35K-$50K, 10-12 weeks)
```

**Test Case 3: Software-Only Device (SaMD)**

```
Device: AI diabetic retinopathy screening (no hardware)
ISO 10993-1: NOT APPLICABLE ‚úÖ (no patient-contacting hardware)
IEC 62304: ‚úÖ REQUIRED (software lifecycle)
  Additional context: Clinical validation ($90K-$145K, 12 weeks)
```

**Acceptance Criteria:**
- ‚úÖ **Conditional logic** correctly excludes N/A standards
- ‚úÖ **Device-specific context** added (e.g., clinical validation for SaMD)
- ‚úÖ **Warnings** shown when standard may/may not apply (e.g., "IF device has electrical components")

---

## 10. Expert Review Requirements

### 10.1 Reviewer Qualifications

**MANDATORY Qualifications:**

| Requirement | Minimum Standard |
|-------------|-----------------|
| **Role** | Standards Testing Engineer OR Testing Laboratory Manager |
| **Experience** | ‚â•12 years in medical device testing (ISO/IEC 17025 environment) |
| **Standards Expertise** | Direct experience with ‚â•3 of: ISO 10993, IEC 60601-1, ISO 11135, ASTM F-series |
| **Accreditation Knowledge** | Familiarity with ISO/IEC 17025, ANAB, A2LA accreditation processes |
| **Device Testing Experience** | ‚â•50 medical device test programs across ‚â•3 product categories |
| **FDA Regulatory Knowledge** | Understanding of FDA testing expectations (510(k), PMA) |

**DISQUALIFIED Reviewers:**

- ‚ùå Software developers (lack testing lab experience)
- ‚ùå Regulatory consultants WITHOUT hands-on testing experience
- ‚ùå Sales staff from testing laboratories (conflict of interest)
- ‚ùå Anyone with <10 years medical device testing experience

---

### 10.2 Review Process

**Step-by-Step Review Protocol:**

**Phase 1: Sample Size Verification (2 hours)**

1. Select 10 standards randomly (2 per category: biocompat, electrical, sterilization, mechanical, software)
2. For each standard:
   - Compare tool's sample size vs. standard text (cite specific section)
   - Verify statistical rationale (e.g., "Why N=5 for cytotoxicity?")
   - Check FDA guidance overlay (does FDA expect more?)
3. Calculate accuracy: (# correct / 10) √ó 100% = ‚â•90% target

**Phase 2: Cost Verification (3 hours)**

1. Select 5 standards (1 per category)
2. Obtain actual lab quotes (‚â•2 labs per standard)
3. Compare tool estimate vs. quotes:
   - Within ¬±30%? ‚Üí PASS
   - Outside ¬±30%? ‚Üí FAIL (identify root cause)
4. Calculate accuracy: (# within range / 5) √ó 100% = ‚â•80% target

**Phase 3: Lead Time Verification (2 hours)**

1. Select 5 standards (same as Phase 2)
2. Verify lead times:
   - Ask labs for typical turnaround
   - Account for queue + testing + report
   - Check if tool includes sequential dependencies
3. Calculate accuracy: (# within ¬±2 weeks / 5) √ó 100% = ‚â•80% target

**Phase 4: Lab Accreditation Verification (2 hours)**

1. Select 10 labs randomly from directory
2. For each lab:
   - Verify ISO/IEC 17025 accreditation exists (check ANAB/A2LA website)
   - Verify scope includes specific standard/method
   - Verify accreditation is current (not expired)
   - Check contact info (website, email, phone)
3. Calculate accuracy: (# valid / 10) √ó 100% = 100% target (zero tolerance)

**Phase 5: Template Verification (3 hours)**

1. Select 3 templates (biocompatibility, electrical safety, sterilization)
2. For each template:
   - Verify all required standard sections included (checklist)
   - Verify device-specific placeholders exist
   - Verify acceptance criteria unambiguous
   - Verify FDA alignment (guidance citations)
3. Calculate completeness: (# complete sections / total sections) √ó 100% = 100% target

**Phase 6: Integration Testing (2 hours)**

1. Run tool on 3 diverse devices:
   - Simple (e.g., wound dressing)
   - Complex (e.g., powered surgical device)
   - Novel (e.g., SaMD)
2. Evaluate integrated output:
   - Is context seamlessly integrated? (not separate file)
   - Are conditional standards correctly applied?
   - Is total cost rollup accurate?
   - Is critical path identified?

**Total Review Time: 14 hours**

---

### 10.3 Review Sign-Off Form

**TICKET-021 Expert Review Sign-Off**

**Reviewer Information:**
- Name: ___________________________________
- Title: ___________________________________
- Organization: ___________________________________
- Years Experience (Medical Device Testing): ___________
- ISO/IEC 17025 Lab Affiliation: ___________________________________
- Date: ___________________________________

**Verification Results:**

| Metric | Target | Actual | Pass/Fail |
|--------|--------|--------|-----------|
| **Sample Size Accuracy** | ‚â•90% | ______% | ‚òê PASS ‚òê FAIL |
| **Cost Accuracy** | ‚â•80% | ______% | ‚òê PASS ‚òê FAIL |
| **Lead Time Accuracy** | ‚â•80% | ______% | ‚òê PASS ‚òê FAIL |
| **Lab Accreditation** | 100% | ______% | ‚òê PASS ‚òê FAIL |
| **Template Completeness** | 100% | ______% | ‚òê PASS ‚òê FAIL |
| **Contact Information** | 100% | ______% | ‚òê PASS ‚òê FAIL |

**Qualitative Evaluation:**

| Question | Yes | No | Comments |
|----------|-----|-----|----------|
| Can you use this output to plan a test program WITHOUT additional research? | ‚òê | ‚òê | ________________ |
| Are sample sizes realistic and defensible to FDA? | ‚òê | ‚òê | ________________ |
| Are cost estimates useful for budgeting? | ‚òê | ‚òê | ________________ |
| Are lead times actionable for project planning? | ‚òê | ‚òê | ________________ |
| Are lab recommendations trustworthy? | ‚òê | ‚òê | ________________ |
| Are templates usable without modification? | ‚òê | ‚òê | ________________ |

**Overall Recommendation:**

‚òê **APPROVED** - Tool meets all acceptance criteria. Ready for production release.

‚òê **CONDITIONAL APPROVAL** - Tool meets 5/6 metrics. Deficiencies documented below. Fix within 30 days.

‚òê **REJECTED** - Tool meets ‚â§4 metrics. Requires significant rework before re-review.

**Deficiencies (if applicable):**
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________

**Reviewer Signature:** ___________________________________

**Date:** ___________________________________

---

## 11. Data Source Documentation

### 11.1 Sample Size Data Sources

**PRIMARY SOURCES (Authoritative):**

| Data Type | Source | Example |
|-----------|--------|---------|
| **Standard-specified sample sizes** | Published standard text | ISO 10993-5:2009, Section 8.3.2: "N=5 devices" |
| **FDA-modified sample sizes** | FDA guidance documents | FDA Sterilization Guidance (1993): "‚â•3 validation runs" |
| **Statistical rationale** | Standard annexes OR statistical textbooks | ISO 10993-1, Annex B: "Sample size determination" |

**SECONDARY SOURCES (Verification):**

| Data Type | Source | Example |
|-----------|--------|---------|
| **Lab recommendations** | Testing lab protocols | Nelson Labs SOP-BIO-005: "Cytotoxicity N=5 minimum" |
| **Industry practice** | AAMI/ASTM technical reports | AAMI TIR45: "Guidance on biological evaluation" |
| **Academic literature** | Journal articles on test validation | J Biomed Mater Res: "Sample size for biocompatibility" |

**Data Update Frequency:**
- **Standards text:** Updated when standard revised (typically 5-year cycle)
- **FDA guidance:** Quarterly review (FDA updates unpredictably)
- **Lab protocols:** Annual review (labs rarely change sample sizes)

---

### 11.2 Cost Data Sources

**PRIMARY SOURCES (Most Reliable):**

| Source | Reliability | Update Frequency | Example |
|--------|-------------|------------------|---------|
| **Direct lab quotes** | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê (100%) | 12 months | Email quote from Nelson Labs (2026-01-10) |
| **Lab published price lists** | ‚≠ê‚≠ê‚≠ê‚≠ê (90%) | Annual | NAMSA Testing Services Catalog (2026 edition) |
| **Industry surveys** | ‚≠ê‚≠ê‚≠ê (70%) | Annual | Medical Device & Diagnostic Industry (MDDI) Survey |

**UNACCEPTABLE SOURCES:**

- ‚ùå Online forums/Reddit (unreliable, outdated)
- ‚ùå Marketing materials (often low-ball estimates)
- ‚ùå Single lab quote (not representative of market)

**Documentation Requirements:**

```json
{
  "standard": "ISO 10993-5:2009",
  "cost_range": [2000, 3500],
  "data_sources": [
    {
      "type": "direct_quote",
      "lab": "Nelson Labs",
      "date": "2026-01-10",
      "amount": 2800,
      "contact": "sales@nelsonlabs.com",
      "quote_number": "Q-2026-00145"
    },
    {
      "type": "published_price_list",
      "lab": "NAMSA",
      "date": "2026-01-01",
      "amount": 2200,
      "source": "NAMSA Testing Services Catalog 2026, Page 12"
    }
  ],
  "last_verified": "2026-02-15",
  "next_review": "2027-02-15"
}
```

---

### 11.3 Lead Time Data Sources

**PRIMARY SOURCES:**

| Source | Reliability | Example |
|--------|-------------|---------|
| **Lab capacity schedules** | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê | Nelson Labs email: "Current queue is 2 weeks for biocompat" |
| **Actual project experience** | ‚≠ê‚≠ê‚≠ê‚≠ê | Historical data: Last 10 ISO 10993-5 projects averaged 2.5 weeks |
| **Lab published turnaround times** | ‚≠ê‚≠ê‚≠ê | NAMSA website: "Standard turnaround: 3-4 weeks" |

**ADJUSTMENTS:**

| Factor | Adjustment | Example |
|--------|-----------|---------|
| **Seasonal demand** | +1-3 weeks (Q4) | Q4 2025: Biocompat queue was 4 weeks (vs. 2 weeks Q1) |
| **Rush service** | -30% to -50% | Rush ISO 10993-5: 1 week (vs. 2-3 weeks standard) |
| **Novel tests** | +50% to +100% | First-time hemocompatibility: 12 weeks (vs. 6 weeks standard) |

---

### 11.4 Lab Directory Data Sources

**PRIMARY SOURCES:**

| Data Type | Source | Verification Frequency |
|-----------|--------|----------------------|
| **Accreditation status** | ANAB database (https://anab.ansi.org)<br>A2LA database (https://www.a2la.org) | Quarterly |
| **Scope of accreditation** | Lab's Scope Certificate (PDF download) | Quarterly |
| **FDA recognition** | FDA ASCA database (https://www.fda.gov/asca) | Quarterly |
| **Contact information** | Lab website + phone verification | Annually |

**Automated Verification Process:**

```python
# Pseudocode for quarterly lab verification
def verify_lab_accreditation(lab_name):
    """Verify lab accreditation is current"""

    # Step 1: Check ANAB database
    anab_status = query_anab_database(lab_name)
    if anab_status['expired']:
        flag_for_review(lab_name, "ANAB accreditation expired")

    # Step 2: Download scope certificate
    scope_pdf = download_scope_certificate(anab_status['cert_number'])
    standards_in_scope = parse_scope_pdf(scope_pdf)

    # Step 3: Verify contact info
    website_status = check_url(lab.website)  # HTTP 200?
    email_status = verify_email(lab.email)   # No bounce?

    # Step 4: Update database
    update_lab_record(lab_name, {
        'accreditation_verified': True,
        'last_verified': today(),
        'next_review': today() + 90_days
    })
```

---

### 11.5 Template Data Sources

**PRIMARY SOURCES:**

| Template Type | Source | Example |
|--------------|--------|---------|
| **Standard requirements** | Published standard text | ISO 10993-5:2009, Clause 11 (report format) |
| **FDA-accepted protocols** | FDA guidance documents | FDA "Use of ISO 10993-1" Guidance (2016) |
| **Industry best practices** | AAMI/ASTM technical reports | AAMI TIR45:2020 "Guidance on biological evaluation plan" |
| **Lab protocols** | Testing lab SOPs (if publicly available) | Nelson Labs cytotoxicity SOP (publicly available excerpt) |

**Template Validation:**

1. **Peer Review:** ‚â•2 testing engineers review template for completeness
2. **Lab Feedback:** Send template to ‚â•1 accredited lab for review ("Would you accept this protocol?")
3. **FDA Alignment Check:** Compare template to ‚â•3 cleared 510(k) submissions (verify FDA accepted similar protocols)

---

## 12. Update and Maintenance Verification

### 12.1 Cost Update Triggers

**AUTOMATIC UPDATE (Annual):**

```
IF current_date >= last_cost_update + 12_months:
    trigger_cost_update()
    obtain_new_lab_quotes(standards=ALL)
    update_cost_ranges()
```

**IMMEDIATE UPDATE (Cost Shift ‚â•30%):**

```
IF spot_check_reveals_cost_change >= 30%:
    flag_critical_update()
    obtain_new_quotes(affected_standards)
    update_database()
    notify_users("Cost data updated due to market shift")
```

**Example:**

```
2026-02-15: Spot check reveals ISO 11135 EO validation now costs $60K-$75K (previously $35K-$50K)
Cause: Lab capacity shortage + inflation
Action: IMMEDIATE update triggered, all sterilization standards re-quoted
```

**Acceptance Criteria:**
- ‚úÖ **Annual cost review** completed (100% of standards re-quoted)
- ‚úÖ **Spot-check** performed quarterly (10 standards randomly selected)
- ‚úÖ **‚â•30% cost change** triggers immediate update (within 2 weeks)

---

### 12.2 Lead Time Update Triggers

**QUARTERLY UPDATE (Lab Capacity Changes):**

```
IF lab_reports_capacity_change:
    update_lead_times(affected_lab, affected_standards)
    add_note("Lab queue increased due to high demand")
```

**Example:**

```
2026-01-15: Nelson Labs notifies: "Q1 biocompat queue now 3 weeks (was 2 weeks)"
Action: Update ISO 10993-5/10/11 lead times from "2-3 weeks" to "3-4 weeks"
Note added: "Increased demand in Q1 2026"
```

**Acceptance Criteria:**
- ‚úÖ **Quarterly lead time review** with ‚â•3 labs
- ‚úÖ **Lab capacity alerts** processed within 1 week
- ‚úÖ **Seasonal adjustments** applied (Q4 rush warning)

---

### 12.3 Lab Accreditation Check

**AUTOMATED QUARTERLY CHECK:**

```python
def quarterly_accreditation_check():
    """Verify all labs have current accreditation"""

    for lab in lab_directory:
        # Check ANAB/A2LA database
        accred_status = check_accreditation(lab.accreditation_number)

        if accred_status == 'EXPIRED':
            flag_lab(lab, status='CRITICAL - Accreditation expired')
            remove_from_directory(lab)  # Do not show expired labs to users

        elif accred_status == 'EXPIRING_SOON' (within 60 days):
            flag_lab(lab, status='WARNING - Verify renewal')
            contact_lab(lab, "Please confirm accreditation renewal status")

        elif accred_status == 'VALID':
            update_lab(lab, last_verified=today())
```

**Acceptance Criteria:**
- ‚úÖ **100% of labs** verified quarterly (no expired accreditation shown to users)
- ‚úÖ **Expiring accreditations** flagged 60 days in advance (proactive renewal check)
- ‚úÖ **Failed verification** triggers immediate removal from directory

---

### 12.4 Template Updates

**STANDARD REVISION TRIGGER:**

```
IF standard_revised (e.g., ISO 10993-5:2009 ‚Üí ISO 10993-5:2025):
    review_template(ISO_10993_5)
    identify_changes (e.g., "Section 8.3.2 now requires N=6, not N=5")
    update_template()
    add_version_note("Updated for ISO 10993-5:2025")
```

**FDA GUIDANCE UPDATE TRIGGER:**

```
IF fda_guidance_updated (e.g., "Use of ISO 10993-1" guidance revised):
    review_affected_templates()
    add_fda_overlay (new FDA expectations)
    update_templates()
```

**Acceptance Criteria:**
- ‚úÖ **Standard revisions** trigger template update within 30 days
- ‚úÖ **FDA guidance updates** reviewed quarterly, templates updated if needed
- ‚úÖ **Version control** maintained (old template archived, new version dated)

---

## 13. Final Acceptance Checklist

**TICKET-021 is COMPLETE when ALL of the following are verified:**

### 13.1 Implementation Complete

- [ ] **Sample sizes** included for ‚â•90% of standards
- [ ] **Cost ranges** included for ‚â•80% of standards
- [ ] **Lead times** included for ‚â•80% of standards
- [ ] **Accredited labs** directory created (‚â•3 labs per standard category)
- [ ] **Protocol templates** created for ‚â•5 standard categories (biocompat, electrical, sterilization, mechanical, software)
- [ ] **Total cost rollup** calculated for device
- [ ] **Critical path** identified (longest lead time sequence)

### 13.2 Verification Complete

- [ ] **Sample size accuracy** ‚â•90% (spot-check 20 standards vs. standard text)
- [ ] **Cost accuracy** ‚â•80% (obtain quotes for 10 standards, verify within ¬±30%)
- [ ] **Lead time accuracy** ‚â•80% (verify 10 standards within ¬±2 weeks)
- [ ] **Lab accreditation** 100% valid (check ANAB/A2LA for ALL listed labs)
- [ ] **Template completeness** 100% (all required standard sections included)
- [ ] **Contact information** 100% current (websites accessible, emails valid)

### 13.3 Expert Sign-Off

- [ ] **Expert reviewer identified** (Standards Testing Engineer, ‚â•12 years experience)
- [ ] **14-hour review** completed (Phases 1-6 per Section 10.2)
- [ ] **Sign-off form** completed (Section 10.3)
- [ ] **Overall recommendation:** APPROVED or CONDITIONAL APPROVAL

### 13.4 Documentation Complete

- [ ] **Data source documentation** created (Section 11)
- [ ] **Update/maintenance procedures** documented (Section 12)
- [ ] **User guide** created (how to interpret test protocol context)
- [ ] **Example outputs** provided for 5 device types (simple/complex/novel/SaMD/combination)

---

## 14. Success Metrics (Post-Release)

**6-Month Post-Release Tracking:**

| Metric | Target | Measurement Method |
|--------|--------|-------------------|
| **User satisfaction** | ‚â•80% find context "actionable" | User survey (N=50+ users) |
| **Time savings** | ‚â•30 min per device (research time eliminated) | User survey + analytics |
| **Lab quote accuracy** | ‚â•75% of users report costs within tool's range | User survey (self-reported) |
| **Template usage** | ‚â•50% of users download templates | Analytics (template download count) |
| **Reduced support tickets** | -30% "Which lab should I use?" tickets | Support ticket analysis |

**12-Month Review:**

- Re-verify cost accuracy (obtain new lab quotes, check if tool ranges still accurate)
- Re-verify lead times (have lab capacities changed?)
- Re-verify lab accreditations (any labs lost accreditation?)
- Update templates if standards revised or FDA guidance changed

---

## Appendix A: Expert Panel Quote Reference

**Source:** EXPERT-PANEL-REVIEW-SUMMARY.md, Lines 154-182

**Testing Engineer's Requirements (Direct Quote):**

> "I need to know:
> 1. **Specific test sections within the standard** - ISO 10993-1 has 12 parts. Which ones?
> 2. **Device-specific parameters** - Contact duration (<24hr, 24hr-30d, >30d)? Temperature? Use cycles?
> 3. **Rationale for EXCLUSIONS** - Client asks 'Do we need ISO 10993-10?' I need to justify YES or NO.
> 4. **Test protocol recommendations** - Sample sizes, lead times, accredited lab recommendations.
>
> **This tool provides NONE of the above.**"

**This verification specification ensures TICKET-021 addresses ALL FOUR requirements.**

---

## Appendix B: Verification Timeline

| Phase | Duration | Deliverable |
|-------|----------|------------|
| **Phase 1: Implementation** | 4 weeks | Code complete, database populated |
| **Phase 2: Spot-Check Verification** | 2 weeks | 20% of standards verified (sample size/cost/lead time) |
| **Phase 3: Lab Accreditation Audit** | 1 week | 100% of labs verified (ANAB/A2LA check) |
| **Phase 4: Template Review** | 1 week | Templates verified complete (checklist) |
| **Phase 5: Expert Review** | 2 weeks | 14-hour review + sign-off |
| **Phase 6: Documentation** | 1 week | User guide, maintenance procedures |
| **TOTAL** | **11 weeks** | **TICKET-021 VERIFIED COMPLETE** |

---

**Document Status:** APPROVED FOR IMPLEMENTATION
**Created:** 2026-02-15
**Next Review:** Upon TICKET-021 implementation complete
**Owner:** Standards Testing Engineer (TBD)
